Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine

CAB+RPV represents a paradigm shift in HIV management, offering a valuable alternative for virologically suppressed individuals seeking freedom from daily dosing. Its successful implementation requires careful patient selection, robust systems to support timely injections, and strategies to mitigate pharmacokinetic challenges. Future directions include expanding eligibility to broader populations, optimizing ultra-long-acting formulations, and integrating injectables into differentiated care models to ensure equity of access.